Stockreport

CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

CervoMed Inc.  (CRVO) 
PDF Aligned with U.S Food and Drug Administration (FDA) on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies (DLB) Reporte [Read more]